Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Opioid Use Disorder

Clinical and regulatory intelligence for Opioid Use Disorder with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
8
Catalysts
0
Assets
5

Relevant assets

Clinical →
FDA →
Mirtazapine →
Pilot →
VA →

Relevant companies

Abbott →

Recent signals(8)

ClinicalJuly 20, 2026

Gut microbiota dynamics linked to opioid use disorder in mouse model

The study reveals that morphine-induced gut microbiota dysbiosis may contribute to compulsive drug-seeking behavior in mice, with significant differences in microbiota stability between compulsive and non-compulsive subjects.

Clinical
July 4, 2026

Pilot Study on Opioid Use Disorder Treatment for Patients with Serious Injection Related Infections

A pilot study is assessing an adapted intervention for Opioid Use Disorder treatment in patients hospitalized with serious injection related infections.

ClinicalJuly 4, 2026

Mirtazapine Shows Promise for Treating Methamphetamine Use in Opioid Disorder Patients

A clinical trial is evaluating Mirtazapine's efficacy in reducing methamphetamine use among opioid use disorder patients receiving medication-assisted treatment.

ClinicalJune 30, 2026

Study on Social Risk-Informed Care for Opioid Use Disorder in ED

A clinical trial is evaluating a new clinical decision support tool aimed at improving treatment adherence for opioid use disorder in the emergency department.

ClinicalJune 29, 2026

Clinical Trial on Extended-release Buprenorphine for Opioid Use Disorder Induction

A clinical trial is underway to evaluate the safety and pharmacokinetics of extended-release buprenorphine as a low-dose induction strategy for Opioid Use Disorder.

ClinicalJune 24, 2026

VA Study to Test Values-Based Intervention for Veterans in Buprenorphine Treatment

A new study will evaluate a brief, values-based intervention aimed at improving interpersonal functioning in Veterans undergoing early buprenorphine treatment.

ClinicalJune 19, 2026

Pilot Study on Deep Brain Stimulation for Opioid Use Disorder Initiated

A pilot study is underway to assess the safety and efficacy of deep brain stimulation targeting the nucleus accumbens in patients with treatment-refractory opioid use disorder.

RegulatoryJune 11, 2026

FDA Clears Bridge Device for Opioid Use Disorder Treatment; Efficacy Under Evaluation

The Bridge Device has received FDA clearance for the treatment of Opioid Use Disorder, emphasizing safety over efficacy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Addiction →
Addiction Medicine →
Neurology →
Opioid Use Disorder →
Substance Use Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.